UFC Headliner Fails Drug Test, Condit Added To UFC 171, Fighters Pick Silva - Weidman 2

- With the highly anticipated UFC 168 rematch between Chris Weidman and Anderson Silva quickly approaching, check out the video above to hear which fighter the pros believe will emerge victorious in the second go-round. Daniel Cormier, Tim Kennedy and a handful of other fighters picked Weidman to win again, while Junior dos Santos, Gilbert Melendez, Cain Velasquez, John Dodson and Jake Shields believe Silva will reclaim his title.

UFC 168 takes place on December 28 from the MGM Grand Garden Arena in Las Vegas. Make sure you join us on the day for our round-by-round live coverage of the event.

- Illustrating once again that MMA has a major problem with TRT (testosterone replacement therapy), Antonio "Bigfoot" Silva registered elevated levels of testosterone on the day of his epic fight with Mark Hunt.

MMAJunkie reports that, though Silva had received approval from the UFC (acting as its own regulatory body while hosting UFC Fight Night 33 in Australia) to undergo TRT, he tested outside of the allowable limit on fight day. As a result, Silva's result was changed from a draw to a No Contest (Hunt will keep a draw on his record), he had his $50,000 Fight of the Night bonus revoked (and given to Hunt) and he will be suspended for nine months.

- With Georges St-Pierre having vacated his title indefinitely, the UFC is acting quickly to sort out the welterweight title picture. That's why, on the same card that it's organized a fight for the vacant belt between Johny Hendricks and Robbie Lawler, it's put together a bout between top welterweight contenders Carlos Condit and Tyron Woodley.

Both Condit and Woodley are coming off of impressive wins, Condit having knocked out Martin Kampmann and Woodley having done the same to Josh Koscheck. Both men rebounded from disappointing losses with those victories. Condit and Woodley will square off at UFC 171, which takes place on March 15 at the American Airlines Center in Dallas, Texas.


Back To Top